Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Summary

This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.

Timeline

Start

2026-06-08

Primary completion

2027-12-03

Completion

2028-02-25

Drugs

Indications